Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
CalciMedica ( (CALC) ) has provided an update.
On January 28, 2026, CalciMedica announced it had discontinued its Phase 2 KOURAGE clinical trial of Auxora in patients with Stage 2 or 3 acute kidney injury with associated acute hypoxemic respiratory failure, following a recommendation from the trial’s Independent Data Monitoring Committee after an interim review raised a safety concern related to study design and patient enrollment criteria. While no deaths were deemed related to Auxora or placebo and no serious adverse events required expedited reporting to the FDA, the company has halted the study, will conduct a comprehensive analysis of the unblinded data to understand the role of baseline characteristics and disease factors in patient outcomes, and has notified regulators while ensuring enrolled patients complete 90-day follow-up, even as it continues to position Auxora and its broader CRAC inhibitor portfolio for potential future trials and indications in high-need inflammatory conditions.
The most recent analyst rating on (CALC) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on CalciMedica stock, see the CALC Stock Forecast page.
Spark’s Take on CALC Stock
According to Spark, TipRanks’ AI Analyst, CALC is a Neutral.
The score is held down primarily by weak financial fundamentals (no revenue, continued losses/cash burn, and a weakened balance sheet with negative equity and added debt). Technicals are a notable offset, showing strong upward momentum above key moving averages. Valuation is constrained by losses (negative P/E), while the expanded stock offering modestly improves funding flexibility but adds dilution risk.
To see Spark’s full report on CALC stock, click here.
More about CalciMedica
CalciMedica Inc. is a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic diseases. Its lead product candidate, Auxora, has shown positive clinical results in multiple completed efficacy trials, including studies in acute pancreatitis with systemic inflammatory response syndrome and severe COVID-19 pneumonia, while a second CRAC inhibitor, CM5480, is being advanced as a potential therapy for pulmonary arterial hypertension.
Average Trading Volume: 86,065
Technical Sentiment Signal: Buy
Current Market Cap: $75.22M
Learn more about CALC stock on TipRanks’ Stock Analysis page.